Alopecia Areata Research Study
We welcome you to take part in a research study exploring the financial burden of living with alopecia areata in adults. The purpose of this study is to better understand the direct and indirect costs associated with alopecia areata, including healthcare use, out-of-pocket expenses, time spent on care, and impacts on work, school,
OLUMIANT® Receives Health Canada Approval, Becoming the Second Approved Treatment for Severe Alopecia Areata in Canada
Eli Lilly Canada Inc. announced today that OLUMIANT (baricitinib) received regulatory approval for its severe alopecia areata indication via Notice of Compliance (NOC) from Health Canada.
LITFULO™ Receives Health Canada Approval, Becoming the First Approved Treatment for Severe Alopecia Areata in Canada
This press release was posted on Pfizer's website on December 4, 2023. A dual JAK3/TEC inhibitor, LITFULO™ (ritlecitinib) is approved for adults and adolescents over 12 years of age for treatment of severe alopecia areata. KIRKLAND, QC, December 4, 2023 – Today, Pfizer Canada announced that Health Canada has granted a Notice of Compliance
A New Treatment for Severe Alopecia Areata Has Been Approved in the USA!
Learn about a new alopecia treatment in the US.
The Burden of Disease in Alopecia Areata: Canadian Online Survey of Patients and Caregivers
The results of the first Canadian study on the burden of disease in Alopecia Areata are now published! This research reveals the psychosocial and financial impacts of alopecia areata on patients and caregivers. Link to the full article is within.
Concert Pharmaceuticals CTP‑543: Is a second FDA-approved treatment for alopecia areata on its way?
Concert Pharmaceuticals reports more positive topline results for CTP-543 as they prepare to submit for FDA approval in the first half of 2023. How exciting!
Watch Dr. Donovan’s update from 2020 and learn about recent advancements in alopecia research.